San Diego-based Capstan is developing a potential first-in-class therapy to treat certain autoimmune disease by changing ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type-1 diabetes, hepatitis, ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

By Christy Santhosh (Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan ...

AbbVie (ABBV) on Monday announced that it has entered into a definitive agreement to acquire privately held clinical-stage biotechnology company Capstan Therapeutics, Inc., in a bid to boost its ...

NORTH CHICAGO, IL and SAN DIEGO, CA, USA I June 30, 2025 I AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology ...

The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.

In the fight against cancer, immunotherapy—which aims to boost the body's natural defenses against cancer—is experiencing ...

A letter to the US public on the AMA website, signed by 75+ medical societies, stresses the vital importance of influenza, RSV, and COVID-19 vaccines.

Examples of specific types of immunotherapies include dendritic cell therapy (sipuleucel-T), adoptive T-cell therapy (CAR-T), antibody therapy (anti-CD47, anti-GD2, anti-CD52, anti-PD-L1, anti-SLAMF7, ...

Nature Reviews Immunology - This Review discusses how the diversity of glycan structures that are produced in the secretory pathway and are displayed at the cell ... Nature Chem. Biol. 1, ...

NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent ...